Phase 1 dose escalation study of sorafenib with palliative radiation therapy : The TAP study

Trial Profile

Phase 1 dose escalation study of sorafenib with palliative radiation therapy : The TAP study

Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2018

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Cancer; Hepatocellular carcinoma; Renal cell carcinoma; Thyroid cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 13 Feb 2018 According to results published in the Radiotherapy and Oncology, trial was terminated early as slow accrual and sorafenib-related systemic toxicity prevented efficient evaluation of RT-related DLTs.
    • 13 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top